A new systematic review reveals promising results for oncolytic viral therapy in treating nonmelanoma skin cancers and ...

Delytact (teserpaturev) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) that was approved for marketing in Japan earlier this year, and received pricing approval in ...

It's not the first therapy in the oncolytic virus class to be approved around the world, as that accolade went to Amgen's Imlygic (talimogene laherparepvec), which was cleared by the FDA for the ...

A new generation of therapeutics, notably including adoptive cell transfer with tumor-infiltrating lymphocyte and T-cell receptor (TCR) engineered T cells, oncolytic virus therapy, and CD3 bispecific ...

The research reveals ... Nasal Spray H5N1 Avian Influenza Vaccine Developed Apr. 8, 2025 — Scientists have pioneered an influenza virus vector-based nasal spray vaccine platform and developed a ...

Given the success of Volume I and Volume II of this Research Topic, and how rapid the subject area is evolving, we are pleased to announce the launch of Oncolytic Virotherapy - Volume III. Using ...

Discover the perfect gift for every occasion. These deep dives offer unique and expert perspectives on tech and other topics that matter most in our daily lives.